Chapter 11: Antipsychotic Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So when you first open a pharmacology textbook, you're kind of sold this very comforting illusion.

Oh, absolutely.

The magic bullet theory.

Right.

You have a medical problem, you take a pill, the drug hits exactly one target in your body and boom, you are cured.

If only it were that simple.

Yeah, it's a clean narrative.

It's incredibly easy to memorize.

But today, we are taking on antipsychotic drugs and we're going to just shatter that illusion completely.

We really are.

Because when it comes to the central nervous system, there are no precision lasers.

We are dealing with messy, clumsy biological tools.

So welcome to this deep dive.

Glad to be here.

If you are studying pharmacology and trying to crack the code of Chapter 11 from Lippincott Illustrated Reviews Pharmacology, you're in the exact right place.

Our mission today is to take this really dense web of drug names, receptor targets and side effects and actually make it make sense.

And you know, the only way to truly understand this class of drugs is to just throw out the idea of simple memorization.

Yeah.

Flashcards won't save you here.

Right.

You have to focus on the why.

We're going to follow the chapter and trace the logic from the ground up.

Start with the foundation.

Exactly.

We'll start with the underlying brain physiology of psychosis.

Look at the specific receptors these drugs accidentally and purposefully hit.

And then translate those microscopic interactions into the massive clinical effects you see in a patient.

Because if you understand the mechanism, right, that huge list of adverse effects goes from just a random list to like a predictable chain of events.

Precisely.

It all cascades from the mechanism.

OK, so let's lay the physiological groundwork first.

We are talking primarily about treating schizophrenia here.

Yes.

And the text defines this as a chronic psychosis that affects about one percent of the population.

It usually emerges in late adolescence or early adulthood.

Which is such a critical time in someone's life, too.

Yeah, it really is.

And it's characterized by severe delusions, hallucinations like hearing voices,

and major disturbances in thought processes.

And physiologically, the root of this is linked to a dysfunction in very specific dopamine pathways in the brain.

Right.

The text mentions overactivity in the mesolimbic pathway and dysfunction in the mesocortical pathway.

Which brings us to the central kind of sobering reality of this entire class of medications.

They aren't cures.

Exactly.

What's fascinating here is that treating schizophrenia involves a really brutal trade -off.

Yeah.

You are balancing the massive benefit of turning down the volume on those terrifying hallucinations just so a patient can function against a truly staggering variety of adverse physical effects.

Every time a physician prescribes these, they are walking a tightrope.

So if the first drugs we invented required such a brutal trade -off, I imagine pharmacologists like immediately started looking for a workaround.

Oh, they definitely tried.

Is that what led to the different generations of these drugs?

Yeah.

Because figure 11 .1 in the text divides them pretty cleanly into two main eras.

Right.

The first generation and second generation.

Yeah.

First generation are the older conventional ones, and second generation are the atypical ones.

But within that first generation,

the drugs are split again into low potency like chlorpromazine and high potency like haloperidol.

Yes.

That's a crucial distinction.

So naturally, as a student, my brain goes, OK, let's unpack this.

Does high potency mean haloperidol actually works better at curing schizophrenia than chlorpromazine?

It's the most common trap you can fall into when learning this material.

I knew it.

It's never that simple.

No, it's not.

In this specific context, potency has absolutely nothing to do with clinical effectiveness.

Wait, really?

Nothing at all?

Nothing.

No single antipsychotic drug is inherently better at treating the core positive symptoms of schizophrenia than another.

OK, so what does high potency actually mean then?

When we say a drug like haloperidol is high potency, we strictly mean it has a very high binding affinity for the dopamine D2 receptor.

It grabs on tight.

Exactly.

It latches onto that receptor incredibly tightly.

And because it binds with such an iron grip, it carries a dramatically higher risk of causing extra pyramidal symptoms.

Which are the severe motor movement disorders, right?

Right.

So high potency just means a higher risk of extra pyramidal symptoms, not a higher cure rate.

Wow, OK.

That distinction changes how you read the whole chapter.

A high potency drug isn't just a super cure.

It's just a drug that grabs the dopamine receptor and refuses to let go.

Precisely.

So if those older first generation drugs are so tough on the motor system, it makes sense that the newer second generation drugs like risperidone, olanzapine, cresapine are now the first line therapy.

Yes, they are the standard now.

How did they actually solve the motor issue, though?

Well, they bypassed it by changing the receptor targets.

Instead of just hammering the dopamine receptors, second generation drugs block both serotonin and dopamine.

Ah, dual blockade.

Exactly.

By introducing that dual blockade, they significantly lower the incidence of those debilitating movement disorders.

The tightrope walk remains.

Right.

It always does.

You escape the severe movement issues, but you buy yourself a whole new set of problems.

Metabolic adverse effects.

Yes.

Patients on these newer drugs face a much higher risk of weight gain, hypercholesterolemia, and eventually diabetes.

If it's one pathway, you break another, it is literally never simple.

Never.

And then we have the ultimate outlier in this newer class, which is clozapine.

Ah, clozapine.

The text carves this one out specifically for refractory patients.

We're talking about the 10 to 20 % of individuals who just don't respond to any standard first or second generation therapy.

Right.

For them, clozapine can work wonders, and it has minimal movement side effects, yet it's rarely the first choice.

It's heavily restricted.

And that's because it carries a series of life -threatening risks.

Yeah.

The book highlights this heavily.

We are talking about severe cardiovascular side effects, seizures, and most dangerously, a high risk of bone marrow suppression leading to a granulocytosis.

Which is a sudden catastrophic drop in white blood cells.

Yeah.

The ones that fight off infection.

Exactly.

Because of this, any patient on clozapine must undergo strict, mandatory, and frequent blood tests just to monitor their white blood cell count.

So it's a drug of last resort, but a highly effective one.

Very effective, yes.

Okay, let's zoom in on what these drugs are actually doing at the microscopic level.

The text has these great figures, like 11 .2.

The receptor blockade diagrams.

Yeah.

If you imagine a nerve terminal in the brain, it's supposed to release little dopamine molecules into the synapse.

Those molecules float across, lock into the D2 receptors on the other side, and trigger a cellular response.

Right, normal physiology.

But first generation antipsychotics essentially act like physical barricades.

Yeah.

They just wedge themselves into those D2 receptors, blocking the dopamine from binding, which decreases that intracellular response.

And the clinical differences emerge when we look at how strongly they bind and what else they bind to, like in figure 11 .3.

Which compares relative affinities.

Haloperidol acts almost entirely on that D2 receptor, with very little interest in the D1 receptor.

Core promizine is more moderate, hitting both.

But the newer drugs are much more complex.

Yeah, I like to think of clozapine's receptor profile as a skeleton key.

That's a great analogy.

Because haloperidol is like a specialized key that only opens one very specific lock, the D2 lock.

But clozapine has a similar affinity for both D1 and D2, plus it possesses a massive affinity for serotonin receptors, specifically the 5 -HT2A receptor.

It unlocks a much broader combination of pathways.

Yeah.

And that intense serotonin blockade is really the defining biochemical feature of the second generation drugs.

Agents like risperidone and olanzapine actually block 5 -HT2A receptors to a much greater extent than they block D2 receptors.

But the feel has evolved even further, creating some truly fascinating outliers.

Like the partial agonists.

Yes.

Drugs like aripiprazole and brexaprazole, they don't just act like an off switch.

I love the analogy of a thermostat for these.

It's very accurate.

If dopamine activity in the brain is running too hot, a partial agonist turns the activity down, but it doesn't shut the furnace off entirely.

It maintains a low baseline level of activity.

A stabilizing effect is a brilliant way to conceptualize it.

Rather than paralyzing the receptor with a full blockade, it just buffers the system.

And there is another incredibly specialized drug mentioned in the text.

Pemavanserin.

Yes.

Consider a patient who has Parkinson's disease.

The fundamental pathology of Parkinson's is a severe lack of dopamine.

Right.

Now, imagine that patient develops psychosis.

If you give them a standard anti -psychotic that blocks dopamine.

You will exacerbate their Parkinson's to a horrific degree.

Exactly.

Enter Pemavanserin.

This drug has absolutely zero appreciable affinity for dopamine receptors.

It only blocks serotonin.

Right.

So you can treat the psychosis without touching the delicate, already depleted dopamine system that Parkinson's patients rely on.

Which perfectly illustrates why knowing the mechanism is so vital.

And it transitions us directly into the clinical actions of these drugs, which are far broader than just treating psychosis.

Because these drugs are not precision tools.

As figure 11 .4 shows, they are messy.

If you picture the brain as a massive, complex switchboard.

These drugs aren't using tiny tweezers to flip the specific dopamine switch they need.

They are swinging a hammer.

I love that.

A hammer.

They hit the dopamine switch, but they clumsily smash the switches for cholinergic, adrenergic, and histamine receptors located right next to it.

Then that's where the side effects come from.

Exactly.

The therapeutic effects come from the intentional dopamine and serotonin blocks, but the massive list of side effects comes from that accidental collateral damage.

Let's actually map that collateral damage, starting with the intended therapeutic action.

By blocking D2 receptors specifically in the mesolimbic system, we reduce the positive symptoms.

The hallucinations, the delusions, the paranoia.

But there are also negative symptoms to schizophrenia.

Right.

Apathy.

A blunted emotional affect.

Yes.

Those are notoriously difficult to treat, especially with older first generation drugs.

The second generation agents tend to be slightly better at ameliorating those negative symptoms.

But the brain has multiple dopamine pathways.

We block the mesolimbic pathway to stop the hallucinations, but what happens when that clumsy hammer also blocks D2 receptors in the migrostriatal pathway?

Well, the migrostriatal pathway is essentially the brain's motor control center.

When you block dopamine there, you disrupt the coordination of movement, leading directly to extrapyramidal symptoms, or EPS.

You are artificially inducing movement disorders to cure a thought disorder.

The hammer strikes again.

But sometimes hitting another pathway is actually incredibly useful.

What about the anti -medic effects?

Figure 11 .5 has these big visual warning signs for this.

Yes.

Treating severe nausea.

We use drugs like prochlorparazine to treat severe nausea, particularly from cancer chemotherapy.

Why does an anti -psychotic stop someone from throwing up?

Because there's an area in the medulla of the brain called the chemoreceptor trigger zone.

The vomit center.

Exactly.

It is essentially the brain's vomit center, and it is rich in dopamine D2 receptors.

When chemotherapy drugs circulate in the blood, they stimulate those receptors, causing intense nausea.

So by administering an anti -psychotic, you block the D2 receptors in that specific trigger zone, effectively disabling the nausea reflex.

Precisely.

That makes perfect sense.

Now let's look at the purely accidental receptor blocks.

The true side effects.

Anticholinergic effects occur when these drugs accidentally block muscarinic receptors.

And that leads to a classic set of symptoms.

Blurred vision, dry mouth, confusion, urinary retention.

The orzine, clopromazine, alanzapine, and clozapine are major culprits here.

But there is one bizarre exception that stands out.

You are referring to the clozapine paradox.

Yes.

Clozapine blocks muscarinic receptors, which physiologically should result in a dry mouth.

Yet it frequently does the exact opposite.

Wait, it increases salivation?

Yes.

It paradoxically increases salivation, to the point where patients on clozapine often struggle with severe, embarrassing drooling.

Oh wow.

The exact mechanism behind this reversed effect is still a mystery, but it is a highly distinctive clinical feature mentioned in the text.

A total paradox.

Let's trace the rest of the switchboard.

What happens when the hammer accidentally smashes the alpha -adrenergic receptors?

You get orthostatic hypotension.

The blood vessels can't constrict quickly enough when the patient stands up, causing their blood pressure to plummet, leading to dizziness or fainting.

Right.

And what if it depresses the hypothalamus?

Well, the hypothalamus regulates body temperature.

If you depress it, you impair thermoregulation.

Which causes what?

A condition called poikilothermia, where the patient's internal body temperature actually begins to fluctuate and match the temperature of the environment around them.

Like a reptile.

Literally like a reptile.

That is genuinely wild to think about.

It really is.

And what if the drug blocks D2 receptors in the pituitary gland?

Dopamine normally acts as a break on the release of prolactin from the pituitary.

When you block dopamine, you remove that break.

So prolactin levels surge.

Exactly.

Which can lead to inappropriate milk production called galacturia, or the enlargement of breast tissue in both men and women.

And finally, the histamine receptors.

Oh yeah.

When these drugs block the H1 histamine receptor, it is exactly like taking a massive dose of Benadryl.

It causes profound sedation.

Drugs like quichapine and lanzapine are heavily sedating precisely because they are so clumsy at avoiding that histamine switch.

Seeing all these interconnected systems really highlights how pervasive neurotransmitters are in regulating behavior and bodily functions.

Which also explains why these medications are used for far more than just schizophrenia.

Exactly.

The alternative therapeutic uses are fascinating.

I was amazed by some of these.

For example, chlorpromazine is actually prescribed to cure intractable hiccups.

Really?

Hiccups?

Yeah.

If you think about it, a hiccup is just an involuntary motor reflex loop.

By dampening dopamine signals in the medulla, you can break that spasmodic cycle.

That's brilliant.

Piemizide is indicated to manage the severe motor and vocal tics associated with Tourette's.

Risperidone helps manage severe irritability secondary to autism.

The pharmacological versatility is undeniable.

But deciding which drug to use is only part of the challenge.

We also have to consider how the body physically handles the drug once it is swallowed.

The pharmacokinetics.

Right.

Most of these agents have variable absorption in the gut that isn't really affected by whether the patient has eaten.

But the exceptions are critical.

Yes.

The absorption of zeprosidone, loracidone, and palperidone is significantly increased if taken with food.

So what does this all mean for a patient who forgets to take their pills?

Because we are talking about patients suffering from paranoia, delusions, and disorganized thinking.

Asking them to maintain perfect daily oral medication adherence is an incredibly tall order.

If they forget to take their pills, the psychosis returns.

Right.

Non -adherence is arguably the biggest hurdle in outpatient psychiatric care.

The pharmaceutical innovation that addresses this is the development of long -acting injectable formulations or LAIs.

Oh, like flufenazine decanoid or risperidone microspheres?

Exactly.

Instead of relying on the patient to swallow a pill every morning, a clinician administers an injection into the muscle.

That injection acts as a depot, slowly releasing the medication into the bloodstream over two to four weeks, and in some newer formulations, up to 12 weeks.

It completely removes the burden of daily adherence.

That sounds like a total game changer for keeping patients stable.

It is.

But even with perfect adherence, we cannot escape the physical toll these drugs take.

Figure 11 .6 has these massive vertical warning signs because the sheer volume of adverse effects is daunting.

Yeah.

Urinary retention,

massive weight gain, increased risk of seizures, debilitating sedation.

The statistics show that adverse effects occur in practically all patients and are considered significant in about 80 % of them.

The burden is immense.

And to truly grasp it, we need to return to the extra pyramidal effects and explain the mechanical why behind them.

Okay, let's break it down.

Think of the striatum in the brain as a perfectly balanced seesaw that controls smooth, coordinated muscle movement.

Sitting on one side of the seesaw, you have inhibitory dopaminergic neurons.

On the opposite side, you have excitatory cholinergic neurons.

And in a healthy brain, they exert equal pressure, keeping the seesaw level.

Exactly.

Ah, I see where this is going.

When we administer an antipsychotic to treat the hallucinations, we block the dopamine.

We effectively kick the dopamine weight off its side of the seesaw.

Right.

Suddenly, that side flies up and there is a massive relative excess of the excitatory cholinergic influence crashing down on the other side.

That severe chemical imbalance is what forces the muscles to spasm and shake.

And the text notes these EPS symptoms appear chronologically.

Within hours to days of starting the drug, a patient might experience dystonia's painful twisting muscle postures.

Then within days to weeks, they develop akathisia.

Which is this agonizing internal motor restlessness where they physically cannot sit still.

And after weeks or months, you see pseudo -Parkinsonism rigidity, resting tremors.

So as a clinician, how do you fix a seesaw when one side is suddenly far too heavy?

You have two theoretical options.

You could stop the antipsychotic medication to let the dopamine return.

But doing so means the terrifying psychosis returns as well.

Exactly.

So you are left with the second option.

You manually push the other side of the seesaw down to restore the balance.

And the text explains you do that by adding an anticholinergic drug.

If you give him something like benzytropine, you block that excess excitatory cholinergic activity.

You force a new artificial balance onto the seesaw, and the movement disorders subside.

A delicate artificial equilibrium.

Of course the cool irony is that to fix the side effects of the first drug, you have to add a second drug which brings its own anticholinergic side effects into the mix.

Like dry mouth and constipation.

Right.

However, there is a vital clinical exception you must remember regarding akathisia.

The severe motor restlessness.

Yes.

It does not respond well to anticholinergic drugs like benzytropine.

To call makathisia, the treatment of choice is actually a beta blocker.

Specifically propranolol.

Ok, good to know.

But that artificial equilibrium might work for a few months.

Schizophrenia is chronic.

What happens when the patient has been taking these dopamine blocking drugs for years, or even decades?

That brings us to one of the most feared complications.

Tardive dyskinesia or TD?

Yeah, this part of the chapter was intense.

If we connect this to the bigger picture, Tardive dyskinesia is a profound demonstration of the nervous system's ability to adapt.

When you subject the brain to long -term, relentless dopamine blockade, the brain assumes something is broken.

It thinks, I'm not getting enough dopamine.

Exactly.

To compensate, the neurons physically synthesize and deploy more dopamine receptors to the surface hoping to catch whatever dopamine is left.

The system becomes intensely hypersensitive.

So now, even with the antipsychotic drug constantly blocking receptors, there are so many new receptors that the dopaminergic input violently overpowers the cholinergic input.

The seesaw flips entirely in the other direction.

This causes uncontrollable, involuntary movements.

Specifically facial tics, jaw clenching, and a very characteristic, irreversible, fly -catching, darting motion of the tongue.

And here's the terrifying part.

If a doctor sees those movements and mistakenly assumes its standard EPS, they might administer benztropine.

But because the seesaw is flipped, benztropine will actually make Tardive dyskinesia significantly worse.

It is a devastating complication.

For decades, it was considered largely untreatable once it set in.

But the text mentions two specific drugs developed to manage it, valbenazine and dutrabenazine.

Yes.

Instead of blocking receptors, they work inside the neuron to deplete the brain's actual storage pools of monoamines, specifically lowering the overall levels of available dopamine.

By reducing the raw amount of dopamine released, they bring the signal strength back down to match the new hypersensitive state of the receptors.

The pharmacology is just brilliant.

It really is.

But the stakes are incredibly high.

Beyond TD, there are acute, life -threatening emergencies that can occur at any time.

Like neuroleptic malignant syndrome.

NMS,

it's rare but catastrophic extreme muscle rigidity, high fever, highly unstable blood pressure.

If this occurs, the antipsychotic must be stopped immediately, and they treat it with dantrolene or bromocryptine to force muscle relaxation.

The cardiovascular risks are equally severe.

Many of these drugs can cause QT interval prolongation in the heart's electrical cycle, which can rapidly deteriorate into fatal arrhythmias.

The older drug theortazine carries a strict black box warning for this.

Right.

And finally, every single antipsychotic medication carries a stark, unavoidable warning.

They cause an increased risk of mortality when used off -label to treat elderly patients suffering from dementia -related behavioral disturbances.

It is an incredibly heavy list of risks to weigh against the benefits, which makes the long -term management of these patients so critical.

Absolutely.

Figure 11 .7 is a line graph showing relapse rates over 800 days.

It clearly shows that atypical drugs like risperidone tend to maintain stability longer and prevent relapses better than older drugs like haloperidol.

But the reality is that after just two psychotic episodes, the recommendation is to maintain drug therapy for at least five years, and many experts advocate for indefinite lifelong therapy.

It's a lifelong journey.

So, to ensure this complex web of mechanisms has really clicked for you, let's look at how this knowledge translates into the tech's study questions.

Let's do a rapid -fire review.

Let's do it.

Say I have a patient with schizophrenia who is mostly free of hallucinations, but they are struggling immensely with a negative symptoms apathy.

Inability to focus.

I know the older drugs won't touch those symptoms.

I need to reach for a second generation atypical.

The text explicitly points out risperidone.

Exactly.

Okay, next one.

Most potent, meaning highest risk for EPS.

Haloperidol.

High binding affinity for D2.

Spot on.

What about the most sedating?

That would be quesapine due to the massive histamine block.

Right.

Okay, here is a tricky one.

A patient on haloperidol is frantically pacing the room, physically unable to stop moving their legs.

Akathisia.

My instinct might be to reach for benestropine to fix the motor issue, but that is the big exception.

For akathisia, I need to administer a beta blocker like propranolol.

Perfect.

What about the highest risk for blood dyscrasias?

Clozapine.

That terrifying risk for granulocytosis.

Frequent blood monitoring is required.

And finally, schizoaffective disorder with secondary insomnia.

You might be tempted to use olanzapine for the sedation, but haloperidone is the correct choice here, strictly based on the text's specific indication logic.

It's the only one FDA approves specifically for schizoaffective disorder.

You nailed it.

You always treat the primary psychiatric indication first.

It takes real discipline not to just chase the side effects.

So true.

Everything traces back to the mechanisms.

The receptors dictate the therapeutic wins, and the accidental collateral damage dictates the side effects.

Before we close this deep dive, I want to leave you with one final thought to mull over.

We spent a significant amount of time exploring tardive dyskinesia, the phenomenon where the brain physically grows new dopamine receptors to bypass the medication you are giving it.

Yeah, the neuroplasticity.

Right.

It is a profound, almost philosophical reminder.

In pharmacology, you are not acting as a mechanic adjusting a static metal machine.

You are wrestling with a living, breathing, highly adaptable nervous system.

It plakes back.

Exactly.

When you introduce a chemical blockade, the brain does not just take it lying down.

It actively rewires its own anatomy to fight back against the changes you are trying to force upon it.

That is deeply humbling and a perfect place to end.

You now have the foundational physiology, the receptor targets, and the mechanical why, behind every single adverse effect in this chapter.

You are more than ready for the exam.

With a warm thank you from the Last Minute Lecture team.